Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford Hospital and Clinics
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-Patients 18 years of age and older presenting to the Stanford Preoperative Evaluation Clinic prior to elective orthopedic surgical procedures or elective vascular surgical procedures not involving the abdominal aorta or carotid arteries.
Exclusion Criteria:
Patients will be excluded from participation if they have one or more of the following conditions:
- Evidence of active local or systemic infection as demonstrated by fever, leukocytosis (white blood cell count > 11,000/ul), productive cough, new infiltrate on chest x-ray, or purulent drainage from any source
- End-stage renal disease
- A history of diabetic neuropathy
- A malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the previous 5 years
- Leukopenia (white blood cell count < 2,000/ul)
- Thrombocytopenia (platelet count < 100,000/ul)
- Abnormal liver function test result (aspartate aminotransferase or alanine aminotransferase level ≥1.5-fold the upper limit of normal)
- A history or infection with tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
- Pregnant or breastfeeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Anakinra
Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
|
An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
Otros nombres:
|
|
Comparador de placebos: Saline injection
Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
|
An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Concentration Levels of Inflammatory Mediators IL-1 Receptor Antagonist (IL-1ra) Present in Human Wounds Following Surgery With and Without the Use of Anakinra.
Periodo de tiempo: Up to 72 hours following surgery
|
Tissue samples were collected at the surgical wound site at 3 time points during the 1st 72 hours following surgery.
Tissue samples from subjects receiving placebo, and subjects receiving anakinra injections pre, and post op were analyzed for IL-1
|
Up to 72 hours following surgery
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Analgesic Consumption During the 72 Hours Following Surgery
Periodo de tiempo: Up to 72 hours following surgery
|
Analgesic consumption is reported as the count of participants receiving each analgesic type. Comparisons between the placebo and active drug groups were made at the conclusion of the study. PCA/IV: Patient controlled Analgesia/ Intravenous |
Up to 72 hours following surgery
|
|
Post-operative Pain Intensity
Periodo de tiempo: Up to 72 hours following surgery
|
Pain was measured on Day 1 and day 2 following surgery using a VAS scale at rest and on stimulation with Visual Analog Scale (VAS) of 1-10 (1=no pain and 10=worst pain)
|
Up to 72 hours following surgery
|
|
Count of Participants Experiencing Wound Infection in the Study From Surgery Till the Time of Discharge From the Hospital
Periodo de tiempo: Up to 72 hours following surgery plus 3 weeks follow-up
|
Evaluation of the surgical wound for symptoms of wound infection was made every day during hospitalization.
Records from the first post-operative clinic visit were also evaluated for evidence of wound infection.
|
Up to 72 hours following surgery plus 3 weeks follow-up
|
|
Count of Participants With Venous Thrombosis After Surgery During Hospitalization
Periodo de tiempo: Up to 72 hours following surgery plus 3 weeks follow-up
|
Evaluation of the surgical wound for symptoms of venous thrombosis was made every day during hospitalization.
Records from the first post-operative clinic visit were also evaluated for evidence of venous thrombosis.
|
Up to 72 hours following surgery plus 3 weeks follow-up
|
|
Assess Rates of Wound Dehiscence
Periodo de tiempo: Up to 72 hours following surgery plus 3 weeks follow-up
|
Evaluation of the surgical wound for symptoms of wound dehiscence was made every day during hospitalization.
Records from the first post-operative clinic visit were also evaluated for evidence of wound dehiscence.
|
Up to 72 hours following surgery plus 3 weeks follow-up
|
|
Total Length of Hospital Stay
Periodo de tiempo: Up to approximately 5 days maximum (admittance to discharge)
|
Total length of hospital stay for patients enrolled in the study.
|
Up to approximately 5 days maximum (admittance to discharge)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Robert L Lobato, MD, Stanford U
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- SU-10312011-8587
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .